Stocktoria
Centessa Pharmaceuticals plc CNTA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-05-28
Centessa Pharmaceuticals plc financials (annual, from 10-K)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $15.0M | $0 | $6.9M | $0 | — | — |
| Operating income | -$207.7M | -$201.1M | -$171.3M | -$212.3M | -$374.1M | -$10.4M |
| Interest expense | — | — | $9.9M | $7.3M | — | — |
| Income tax | $1.8M | $2.8M | -$25.1M | -$747,000 | $114,000 | $0 |
| Net income | -$197.5M | -$235.8M | -$151.1M | -$216.2M | -$381.1M | -$10.7M |
| EPS (diluted) | $-1.46 | $-2.06 | $-1.57 | $-2.31 | $-5.07 | — |
| Operating cash flow | -$193.8M | -$142.1M | -$160.3M | -$200.5M | -$135.1M | -$10.6M |
| Free cash flow | -$194.2M | -$142.1M | -$160.5M | -$201.7M | -$135.3M | -$10.6M |
| Cash & equivalents | $61.3M | $383.2M | $128.0M | $393.6M | $595.1M | $7.2M |
| Total assets | $687.5M | $576.8M | $360.2M | $444.3M | $629.6M | $11.7M |
| Total liabilities | $160.6M | $175.3M | $124.0M | $108.1M | $138.1M | $8.6M |
| Shareholders' equity | $526.9M | $401.5M | $236.2M | $336.2M | $491.6M | — |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001847903 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.